Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Rx For R&D Includes Tandem Drug/Biologic Development

Executive Summary

Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity

You may also be interested in...



Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says

Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date

Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says

Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date

R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME

Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12

Related Content

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel